Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Modulating Th2 Cell Immunity for the Treatment of Asthma.

Authors:
Beatriz León Andre Ballesteros-Tato

Front Immunol 2021 10;12:637948. Epub 2021 Feb 10.

Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.

It is estimated that more than 339 million people worldwide suffer from asthma. The leading cause of asthma development is the breakdown of immune tolerance to inhaled allergens, prompting the immune system's aberrant activation. During the early phase, also known as the sensitization phase, allergen-specific T cells are activated and become central players in orchestrating the subsequent development of allergic asthma following secondary exposure to the same allergens. It is well-established that allergen-specific T helper 2 (Th2) cells play central roles in developing allergic asthma. As such, 80% of children and 60% of adult asthma cases are linked to an unwarranted Th2 cell response against respiratory allergens. Thus, targeting essential components of Th2-type inflammation using neutralizing antibodies against key Th2 modulators has recently become an attractive option for asthmatic patients with moderate to severe symptoms. In addition to directly targeting Th2 mediators, allergen immunotherapy, also known as desensitization, is focused on redirecting the allergen-specific T cells response from a Th2-type profile to a tolerogenic one. This review highlights the current understanding of the heterogeneity of the Th2 cell compartment, their contribution to allergen-induced airway inflammation, and the therapies targeting the Th2 cell pathway in asthma. Further, we discuss available new leads for successful targeting pulmonary Th2 cell responses for future therapeutics.

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2021.637948DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7902894PMC
February 2021

Publication Analysis

Top Keywords

th2 cell
20
allergen-specific cells
8
allergic asthma
8
targeting th2
8
th2
7
asthma
7
cell
5
inflammation neutralizing
4
essential components
4
neutralizing antibodies
4
th2-type inflammation
4
components th2-type
4
targeting essential
4
antibodies key
4
modulators attractive
4
asthmatic patients
4
patients moderate
4
moderate severe
4
option asthmatic
4
attractive option
4

Keyword Occurance

Similar Publications

Oral multivalent epitope vaccine, based on UreB, HpaA, CAT, and LTB, for prevention and treatment of Helicobacter pylori infection in C57BL / 6 mice.

Authors:
Wenwei Xie Wenfeng Zhao Ziling Zou Lingyi Kong Lei Yang

Helicobacter 2021 Apr 12:e12807. Epub 2021 Apr 12.

Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, China.

Background: As the resistance of Helicobacter pylori to traditional triple therapy is gradually revealed, an increasing number of people are focusing on vaccine treatments for H. pylori infection. Epitope vaccines are a promising strategy for the treatment of H. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

The Concept of Pathogenic TH2 Cells: Collegium Internationale Allergologicum Update 2021.

Authors:
Nicole L Bertschi Cecilia Bazzini Christoph Schlapbach

Int Arch Allergy Immunol 2021 Apr 12;182(5):365-380. Epub 2021 Apr 12.

Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

T helper (TH) cells have evolved into distinct subsets that mediate specific immune responses to protect the host against a myriad of infectious and noninfectious challenges. However, if dysregulated, TH-cell subsets can cause inflammatory disease. Emerging evidence now suggests that human allergic disease is caused by a distinct subpopulation of pathogenic TH2 cells. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

A hederagenin-type triterpene saponin, sumbulianoside a from and its potent immunomodulatory activity against seasonal flu virus H3N2.

Authors:
Huseyin Abaci Gulsah Akagac Ayse Nalbantsoy Nazli Boke Sarikahya

Nat Prod Res 2021 Apr 11:1-9. Epub 2021 Apr 11.

Faculty of Science, Department of Chemistry, Ege University, Bornova, Turkey.

A new hederagenin-type triterpene saponin; hederagenin 28-O--D-galactopyranosyl-(1→6)--D-glucopyranosyl ester named sumbulianoside A (), together with twelve known saponins were isolated from the -butanol extract of (Caprifoliaceae) from which, one known saponin, dipsacus saponin A () was isolated, for the first time from species. The structures of the isolated compounds were elucidated by 1 D and 2 D NMR and HRESIMS analyses. Cytotoxic activities were investigated on A549, Hela, PANC1, SHSY5Y cells and non-cancerous cell HEK293 by MTT method and immunomodulatory activities were evaluated against activated H3N2 seasonal virus in whole blood by measuring IL-4, IFN-, IL-1 cytokine level with ELISA. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

IRAK-M knockout promotes allergic airway inflammation, but not airway hyperresponsiveness, in house dust mite-induced experimental asthma model.

Authors:
Xudong Zhang Mingqiang Zhang Lun Li Wei Chen Wexun Zhou Jinming Gao

J Thorac Dis 2021 Mar;13(3):1413-1426

Departments of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Background: IL-1 receptor associated-kinase (IRAK)-M, expressed by airway epithelium and macrophages, was shown to regulate acute and chronic airway inflammation exhibiting a biphasic response in an OVA-based animal model. House dust mite (HDM) is a common real-life aeroallergen highly relevant to asthma pathogenesis. The role of IRAK-M in HDM-induced asthma remains unknown. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

TIGIT-Fc as a Potential Therapeutic Agent for Fetomaternal Tolerance.

Authors:
Wenyan Fu Renfei Cai Zetong Ma Tian Li Changhai Lei Jian Zhao Shi Hu

Front Immunol 2021 25;12:649135. Epub 2021 Mar 25.

Department of Biophysics, College of Basic Medical Sciences, Second Military Medical University, Shanghai, China.

The perfect synchronization of maternal immune-endocrine mechanisms and those of the fetus is necessary for a successful pregnancy. In this report, decidual immune cells at the maternal-fetal interface were detected that expressed TIGIT (T cell immunoreceptor with Ig and ITIM domains), which is a co-inhibitory receptor that triggers immunological tolerance. We generated recombinant TIGIT-Fc fusion proteins by linking the extracellular domain of TIGIT and silent Fc fragments. Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap